

Value Partners Health Care Fund

A Sub-Fund of Value Partners Ireland Fund ICAV

A UCITS-Compliant Fund ¹

NAV per unit: Class A USD Unhedged - USD14.46

Fund size : USD36.8 million



Morningstar Rating ^{TM2}
As at 31-05-2020

Value Partners
Investing through discipline


May 2020

- Value Partners Health Care Fund (the "Fund") primarily invests in equities and equity-related securities in healthcare companies in China or companies which derive a significant part of their revenue from the PRC and which are listed on other worldwide stock markets.
- The Fund may have significant investments in the securities of high growth companies and that these securities may be very volatile. The value of the Fund could decrease substantially within a short time. Investors may lose part or all of their investment.
- The Fund's investments in China are subject to a higher level of market risk than investments in a developed country due to greater market volatility, political and economic instability and governmental limitations etc.
- The Fund may also invest in derivatives and debt securities that are below investment grade or unrated which can involve material risks, e.g. counterparty default risk, insolvency or liquidity risk, and may expose the Fund to significant losses.
- The Fund's investments are primarily denominated in RMB. RMB is currently not a freely convertible currency and is subject to exchange controls and restrictions. Investors whose base currencies of investments are not in RMB should take into account the potential risk of loss arising from fluctuations in value between such currencies and the RMB.
- You should not make investment decision on the basis of this marketing material alone. Please read the prospectus for details and risk factors.

Investment objective

The Fund aims to achieve long-term capital growth by investing primarily in equities and equity related securities in healthcare companies, such as pharmaceuticals, biotechnology, healthcare services, as well as medical technology and supplies, which derive a significant part of their revenue from the PRC and which are listed on stock markets on a worldwide basis, including mainland China.

Performance since launch



Performance update

	Class A USD Unhedged	CSI 300 Index	Hang Seng China Enterprises Index
One month	+1.7%	-2.2%	-4.1%
Three months	+6.5%	-3.7%	-6.1%
Six months	+11.9%	-0.4%	-5.6%
Year-to-date	+6.6%	-7.7%	-13.4%
One year	+17.8%	+5.1%	-3.7%
Three years	+36.2%	+12.8%	+2.4%
Total return since launch	+44.6%	-9.6%	-8.0%
Annualized return since launch ^A	+7.4%	-1.9%	-1.6%

Top holdings

Name	Industry ³	%
CSPC Pharmaceutical Group Ltd	Pharmaceuticals, biotechnology & life sciences	9.3
Sino Biopharmaceutical Ltd	Pharmaceuticals, biotechnology & life sciences	8.1
Hualan Biological Engineering Inc	Pharmaceuticals, biotechnology & life sciences	7.0
Jiangsu Hengrui Medicine Co Ltd	Pharmaceuticals, biotechnology & life sciences	6.4
Yunnan Baiyao Group Co Ltd	Pharmaceuticals, biotechnology & life sciences	6.2

These securities constitute 37% of the Fund.

Portfolio characteristics

As at 29 May 2020	2020 ⁴
Price/earnings ratio	22.5 times
Price/book ratio	3.1 times
Portfolio yield	1.3%

	Class A USD Unhedged	CSI 300 Index	Hang Seng China Enterprises Index
Annualized volatility (3 years) ⁵	14.2%	20.0%	19.4%

Geographical exposure by listing ⁶

China A-shares	50%
Hong Kong	29%
Red Chips	9%
H-shares	8%
United States	2%
Cash ⁷	2%

NAVs & codes

Classes ⁸	NAV	ISIN	Bloomberg
Class A USD Unhedged	14.46	IE00BSM8VZ90	VPHCUAU ID
Class A HKD Unhedged	14.12	IE00BSM8VQ00	VPHCUAH ID
Class A SGD Unhedged	11.22	IE00BSM8VV52	VPHCUAS ID

The Fund – Class A USD Unhedged: Monthly performance from 2 Apr 2015 to 29 May 2020

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Annual
2015	N/A	N/A	N/A	+2.5%	+3.6%	-6.2%	-5.3%	-7.5%	+0.3%	+7.5%	-1.7%	+4.1%	-3.7%
2016	-12.9%	-0.1%	+6.7%	-0.1%	-1.1%	+1.1%	+5.5%	+5.6%	+2.3%	-0.2%	+0.0%	-3.4%	+1.9%
2017	+2.3%	+1.6%	+2.0%	+1.3%	+0.8%	+2.7%	-1.6%	+0.7%	+1.5%	+5.9%	-0.7%	+2.7%	+20.8%
2018	+3.1%	-1.9%	+6.0%	-0.6%	+7.6%	-4.9%	-1.5%	-3.1%	-1.0%	-5.7%	+3.2%	-5.7%	-5.4%
2019	+2.9%	+8.1%	+5.9%	-1.1%	-5.9%	+1.4%	+1.1%	+3.7%	-3.2%	+6.3%	-3.8%	+5.0%	+21.0%
2020 (YTD)	-2.9%	+3.2%	-3.1%	+8.1%	+1.7%								+6.6%

^A Annualized return is calculated from inception based on published NAV.

Fund facts

Manager:	Value Partners Hong Kong Limited
Base currency:	USD
Launch date:	Class A USD Unhedged/HKD Unhedged - 2 Apr 2015 Class Z RMB (CNH) Unhedged - 2 Apr 2015 Class A SGD Unhedged - 19 Jun 2018
Dealing frequency:	Daily, Cutoff time 11:59am Irish time
Legal status:	Authorized by the Central Bank of Ireland as an undertaking for collective investment in transferable securities pursuant to the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations 2011 ¹
Depository:	HSBC France, Dublin Branch
Reporting:	www.valuepartners-group.com

Fee structure

	Class A	Class Z RMB (CNH)
Minimum subscription:	USD10,000 / SGD10,000	RMB10,000,000
Initial subscription fee:	Up to 5% of issue price	
Management fee:	1.5% p.a.	1.0% p.a.
Performance fee ⁹ :	15% of profit (high-on-high)	
Redemption fee:	Currently nil	

Source: HSBC Institutional Trust Services (Ireland) DAC and Bloomberg, data as at the last valuation date of the month as stated above, unless stated otherwise. Performance is calculated on NAV to NAV in base currency with dividend reinvested and net of fees. All indices are for reference only. Our portfolio disclosure policy can be obtained from the Investment Manager upon request to email fis@vp.com.hk.

1. Value Partners Health Care Fund is a sub-fund of Value Partners Ireland Fund ICAV (formerly Value Partners Ireland Fund plc), is an umbrella scheme with segregated liability between sub-funds authorised by the Central Bank of Ireland as an undertaking for collective investment in transferable securities pursuant to the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations 2011. The ICAV is authorised and supervised by the Central Bank. Authorisation by the Central Bank shall not constitute a warranty as to the performance of the ICAV and the Central Bank shall not be liable for the performance or default of the ICAV. 2. © 2020 Morningstar, Inc. All Rights Reserved. 3. Classification is based on Global Industry Classification Standard (GICS). 4. The profile is based on market consensus forecast as derived from FactSet and Bloomberg. Harmonic mean methodology is applied to calculate the forecast P/E ratio and P/B ratio. Note that the manager's internal estimates may differ significantly from FactSet and Bloomberg estimates. 5. Volatility is a measure of the theoretical risk in terms of standard deviation, based on monthly return over the past 3 years. 6. Exposure refers to net exposure (long exposure minus short exposure). Due to rounding, percentages shown may not add up to 100%. 7. Cash includes receivables and payables (except cash for collaterals and margins). 8. All classes are not available for public retail distribution in Hong Kong. 9. Performance fee will only be charged if the NAV at the end of the financial year or upon realization of units exceeds the "high watermark", which is the all-time year-end high of the Fund's NAV. If in any one year, the Fund suffers a loss, no performance fee can be charged in subsequent years until the loss is recovered fully (the high-on-high principle).

No investor should subscribe to the Fund without having read the Prospectus, Supplement and Key Investor Information Documents (in English) which are available at www.valuepartners-group.com.

Recipients of this document who intend to subscribe for the Fund following publication of the Prospectus, Supplement and Key Investor Information Document are reminded that any such application may only be made on the basis of the information contained in the final Prospectus, Supplement and Key Investor Information Documents which may be different from the information contained in this document which may be subject to updating, amendment and/or completion.

No reliance may be placed for any purpose whatsoever on the information contained in this document or on its completeness. No representation or warranty, express or implied, is given by the promoter of the Fund as to the accuracy of the information or opinions contained in this document and no liability is accepted for any such information or opinions.

Investors should note that the Fund is not a guaranteed fund. Value of investment in the Fund can go down as well as up and return upon such investment will therefore necessarily be variable. Neither past experience nor the current situation are necessarily accurate guides to the future. Past performance may not be a reliable guide to future performance. Income may fluctuate in accordance with market conditions and taxation arrangements. Changes in exchange rates may have an adverse effect on the value price or income of the Fund. Investors should also be aware that the Fund may be subject to sudden and large falls in value, in which case investors could lose the total value of their initial investment. Investors should seek advice from a financial adviser before making any investment. In the event that you choose not to do so, you should consider whether the investment selected is suitable for you.

For Swiss investors: This is a marketing document. The sales prospectus or the terms of contract or the Placement Memorandum, the Articles of Association or the Limited Partnership Agreement or the Trust deed as well as the annual and semi-annual reports of the Fund may be obtained free of charge from the Swiss Representative. In respect of the Shares distributed in Switzerland to Qualified Investors, place of performance and jurisdiction is at the registered office of the Representative.

Switzerland Representative: FIRST INDEPENDENT FUND SERVICES LTD, Klausstrasse 33, CH-8008 Zurich.

Switzerland Paying Agent: NPB NEUE PRIVAT BANK AG, Limmatquai 1, CH-8024 Zurich.

This document has not been reviewed by the SFC. Issuer: Value Partners Hong Kong Limited.